Combining immune checkpoint inhibitors (anti-PD-1/PD-L1) with WNT pathway inhibitors can potentially reverse immune suppression in malignant cells, thereby enhancing T cell-mediated tumor clearance64–66. Here, CD274 is linked to neoplasm.